---
title: 'Tisagenlecleucel utilisation and outcomes across refractory, first relapse
  and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis
  of real-world patterns'
date: '2023-11-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37954907/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231114170826&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'BACKGROUND: Tisagenlecleucel was approved by the Food and Drug Administration
  (FDA) in 2017 for refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-ALL
  in ≥2nd relapse. Outcomes of patients receiving commercial tisagenlecleucel upon
  1st relapse have yet to be established. We aimed to report real-world tisagenlecleucel
  utilisation patterns and outcomes across indications, specifically including patients
  treated in 1st relapse, an indication omitted from formal FDA ...'
disable_comments: true
---
BACKGROUND: Tisagenlecleucel was approved by the Food and Drug Administration (FDA) in 2017 for refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-ALL in ≥2nd relapse. Outcomes of patients receiving commercial tisagenlecleucel upon 1st relapse have yet to be established. We aimed to report real-world tisagenlecleucel utilisation patterns and outcomes across indications, specifically including patients treated in 1st relapse, an indication omitted from formal FDA ...